Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

MOLECULAR BASIS OF DISEASE > PATHOLOGIES > Flashcards

PATHOLOGIES Flashcards

1
Q

Anaemia

A

Insufficient O2 carrying capacity due to decrease Hb concentrations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Why is there not enough haemoglobin

A

Bone marrow doesn’t produce enough Hb - hypoproliferation - not enough ingredients or incorrect instructions.
Shortened survival - blood loss, haemolysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Iron absorption

A

Absorbed from duodenum.
Regulated by negative feedback of hepcidin - regulates ferroportin receptors on enterocytes, duodenum and proximal jejunum.
Transferred into plasma and bind to transferrin - transport protein.
Absorption depends on hepcidin, activity of ferroportin and type of iron available.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Iron transport and storage

A

Iron transported from enterocytes to plasma or excess Iron stored as ferritin.
In plasma - attach to transferrin and transported to bone marrow or RBCs.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Where is folate and B12 absrobed from

A 
Folate = duodenum and jejunum
B12 = ileum via intrinsic factor
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Function of folate and B12

A 
Folate = necessary for synthesis of DNA
B12 = co-factor for methylation in DNA and cell metabolism - intracellular conversion to 2 active co-enzymes necessary for homeostasis of methylmalonic acid & homocysteine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Mechanism of absorbing B12

A

Require intrinsic factors made in parietal cells of stomach

Transcobalamin II and transcobalamin I transport vit B12 to tissues

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Pernicious anaemia

A

Autoimmune disorder - lack intrinsic factor - decrease B12 absorption.
Antibodies against gastric parietal cells or intrinsic factor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Macrocytic anaemia

A

Low Hb
High MCV
Norm. MCHC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Haemolytic anaemia

A

Anaemia due to shortened RBC survival

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Haemolysis

A
  1. Shortened red cell survival
  2. Bone marrow compensates - increase RBC production
  3. increase young cells in circulation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Compensated haemolysis

A

RBC production able to compensate for decrease RBC life span = norm Hb

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Incompletely compensated haemolysis

A

RBC production unable to keep up with decrease RBC life span = decrease Hb

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Clinical findings of haemolytic anaemia

A

Jaundice, pallor/fatigue, splenomegaly
Haemolytic crises - increase anaemia and jaundice with infections.
Aplastic crises - anaemia, reticulocytopenia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Chronic clinical findings of haemolytic anaemia

A

Gallstones - pigment due to bilirubin

Folate deficiency - increase synthesis for cells, increase demand because more broken down

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Haemolytic anaemia - laboratory findings

A 
Increased reticulocyte count
Increased unconjugated bilirubin
Increased LDH
Low serum haptoglobin proteins that binds free haemoglobin
Increased urobilinogen
Increased urinary haemosiderin
Abnormal blood film
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Red cell membrane disorders examples

A

Hereditary spherocytosis

Hereditary elliptocytosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Red cell enzymopathies examples

A

G6PD deficiency

PK deficiency

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Hereditary spherocytosis

A

Common haemolytic anaemia - inherited autosomal dominant fashion
defect in protein in vertical interaction between membrane skeleton and lipid bilayer
Decrease membrane deformability - membrane lose shape = RBC spherical

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Clinical features of Hereditary spherocytosis

A

Asymptomatic to severe haemolysis, neonatal jaundice, pigment gallstones.
Decrease eosin-5-maleimide (EMA) binding - binds to band 3

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Glucose 6 phosphate deficiency

A

hereditary, X-linked - protection from oxidative stress

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Effects of oxidative stress on Hb and membrane proteins

A

Hb - denatured Hb - heinz bodies - bind to membrane

Membrane proteins - decrease RBC deformability

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Pyruvate kinase deficiency

A

Autosomal recessive
Required to generate ATP - essential for memrbane cation pumps.
Lose K+ and H2O = dehydrated and rigid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Thalassaemias

A

Imbalanced alpha and beta chain production - excess unpaired globin chains = unstable.
Precipitate and adamage RBC - ineffective erythropoiesis in bone marrow

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Beta thalassaemia major - if transfusion does not occur

A

Failure to thrive, progressive hepatosplenomegaly, bone arrow expansion - skeletal abnormalities.
Side effects = Iron overload - heart failure, liver cirrhosis, endocrinopathoes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Confirming diagnosis of sickle cell anaemia

A

Solubility test - expose blood to reducing agent - HbS precipitate = + trait and disease
Electrophoresis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Steps for Primary haemostasis

A
  1. Endothelium release small amount of von Willebrand factor
  2. Collagen exposed to blood – von Willebrand factor binds to it
  3. Platelets express receptors for both collagen and von Willebrand factor is then active when bound and then express functional fibrinogen receptors – NEEDED for aggregation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Steps for secondary haemostasis

A
  1. Platelet is activated
  2. Tissue factor expressed by many sub-endothelial cells activate coagulation cascade to initiate increase of thrombin
    - Factor FVIIa binds to tissue factor – prothrombin into thrombin
  3. Thrombin activates receptors on platelets and endothelium - increase platelet aggregation and initiate release of stored von Willebrand factor from endothelial cells
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Steps for amplification stage in blood coagulation

A
  1. Thrombin activates 2 cofactors - factor 8a and 5a
  2. Form Ca2+ dependent complexes on surface of platelets with factor IXa and factor Xa - accelerate production of factor Xa and thrombin = amplification stage
  3. Increase production of thrombin via tenase and prothrombinase - thrombin converts fibrinogen into fibrin mesh
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Steps of fibrinolysis

A

Plasminogen activated to plasmin by tissue plasminogen activator (t-PA)
Plasmin degrades the fibrin mesh to fibrin degradation products which can be cleared.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

What is antithrombin

A

Serpin = serine protease inhibitor

Activity increases by binding to heparan binding sites on endothelial cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Protein C

A

Activated by thrombin + thrombomodulin on endothelial cells = APC
then works with protein S

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Protein S

A

APC cofactor

Help bind to cell surface - APC degrades cofactor FVa and FVIIIa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Molecular basis of Haemophlia

A

Failure to clot leading to haemorrhage.
Mutation in cogaultion factors - haemophilia A and B
Platelet disorder - von Willebrand disease
Collagen abnormalities - fragile blood vessels and bruising

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Molecular basis of thrombophilia

A

Excessive clotting leading to thrombosis
Inherited = mutation in coagulation factors (DVT)
Acquired = malignancy increase clotting factors (DVT)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

Molecular basis of DIC

A

Whole body clots
Infection - sepsis
Depletion of clotting factors and platelets leading to bleeding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

Aneuploid

A

Chromosome number is not an exact multiple of haploid number

Extra or missing chromosomes - trisomy or monosomy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

How does aneuploid chromosomes occur

A

Error in segregation of pair of homologous chromosomes in meiosis I
Or when there is an error in segregation of chromatids - meiosis II = imbalance of chromosomes in zygote

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

Trisomy 13

A

Pataus syndrome

complications of heart abdominal wall and brain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

Trisomy 18

A

Edwards syndromes

complex heart and brain abnormalities

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

Trisomy 21

A

Down syndrome
High chance of health problems - congenital heart problems, disorders of digestive tract, visiom and increased risk of leukaemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

Mitotic non-disjunction

A

Post zygotic non-disjunction - affect only a proportion of cells = mosaicism
Individual has a mixture of cell types

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

Trisomy rescue/anaphase lag

A

Mechanism in cell recognise there is a wrong number of chromosomes and throws out one of the chromosomes to become disomic.
Could have both maternal chromosomes - clinical impact

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

Philadelphia chromosome

A

Translocation between chromosome 9 and 22.
ABL on chromosome 9 = proto-oncogene
BCR on chromosome 22 = prone to ds DNA breaks.
Exchange material which can trigger oncogene potential in ABL. Can lead to types of leukaemia and myeloma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

What occurs in Robertsonian translocation

A

Involves acrocentric chromosomes

Ds breaks p arm is cut off and lost - q arms stuck together around centromere

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

Detecting chromosomal abnormalities - what is FISH

A

Hybridisation - single strand nucleic acid strand binds to new single stranded nucleic acid strand - use metaphase chromosome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

Detecting chromosomal abnormalities - steps in FISH

A
  1. Fluorescent probe
  2. Denature probe and target DNA
  3. Mix probe and target DNA
  4. Probe binds to target
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

Steps for array CGH

A
  1. Patient and control DNA labelled with fluorescent dyes and applied to microarray
  2. Patients and control DNA compete to attach or hybridise to the microarray
  3. The microarray scanner measures the dluorescent signals
  4. Computer software analyses the data and generates a plot
    Looks for microdeletions and duplications
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

QF-PCR

A

Uses microsatellites - isolate DNA from patient and make primers
PCR amplification
Gel electrophoresis
Genotype size of fragments

50
Q

What are the effects of inborn errors of metabolism due to

A

Toxic accumulation of substrates
Intermediates from alternative metabolic pathways
Defects in energy production/use due to deficiency of products

51
Q

Example of disease with autosomal recessive inheritance

Inborn errors of Metabolism

A

PKU
Alkaptonuria
MCADD

52
Q

Example of disease with autosomal dominant inheritance

Inborn errors of Metabolism

A

Marfan’s

acute intermittent porphyria

53
Q

Example of disease with X-linked inheritance

Inborn errors of Metabolism

A

Fabry’s disease

Ornithine carbamoyl transferase deficiency

54
Q

Example of disease with Mitochondrial inheritance

Inborn errors of Metabolism

A

MERFF - deafness, dementia, seizures

MELAS - lactic acidosis, stroke like episodes

55
Q

Heteroplasmy - mitochondrial inheritance

A

Cell contains varying amounts of mtDNA and mutated mtDNA

56
Q

Classification of IEM

A

Toxic accumulation
Deficiency in energy production
Disorders of complex molecules involving organelles

57
Q

Clinical scenarios of neonatal presentation of IEM

A 
Poor feeding, lethary, vomiting
Epileptic encephalopathy
Profound hypotonia
organomegaly
Sudden death in infancy
58
Q

Biochemical abnormalities of neonatal presentation of IEM

A

Hypoglycaemia
hyperammonaemia
unexplained metabolic acidosis/ketoacidosis
lactic acidosis

59
Q

Anencephaly

A

opening in anterior portion of neural tube

60
Q

Craniorachischisis

A

Complete opening of neural tube - 1st stage of closing foes not occur properly

61
Q

Spina bifida

A

Opening at caudal end of neural tube

62
Q

Steps for primary neurulation

A
  1. Shaped - will narrow along mediolateral axis and extend along rostral caudal axis
  2. Folding - occurs by establishing hinge points at different regions along neural plate
  3. Elevation - folding of lateral wings of neural plate
  4. Convergence - neural folds converge - form more hinge points in dorsal regions
  5. Closure - fuse with each other and complete closure of neural plate
63
Q

How does Cell wedging occur

A

Change shape of cells in neural plate - apical side = narrow = work as hinge
Remodelling of microtubules and actin filaments - Wnt PCP - control actomyosin cytoskeleton at apical side - contracted along medial lateral axis

64
Q

Wnt PCP pathways association with neural tube formation

A

Controls the remodelling of actomyosin cytoskeleton at apical side of cell - becomes contracted along medial lateral axis = change shape of epithelium = hinge
Mutations in pathway = no hinge = craniorachischisis

65
Q

Proteinopathies involved in Alzheimer’s disease

A
  • Amyloid plaques - extracellular protein aggregates. Enriched in Aβ peptides
  • Neurofibrillary tangles - paired helical filaments - intracellular protein aggregates. Enriched in Tau protein.
66
Q

How do amyloid plaques form

A

Aβ peptides cleaved from transmembrane protein called amyloid β precursor protein (APP) by proteases.
Cleavage by β secretase and then γ secretase – release Aβ fragment – accumulates leading to plaque

67
Q

How do neurofibrillary tangles form

A

Tau binds microtubules in axons - hyperphosphorylated tau = displaced leading to tangles, destabilised.

68
Q

Motor symptoms of parkinsons

A

Resting tremor
bradykinesia
rigidity
postural instability

69
Q

Non-motor symptoms of parkinsons

A

Depression and anxiety
Loss of smell
Sleep disorders
Constipation

70
Q

Proteinopathy involved in parkinsons

A

Lewy bodies - intracellular protein aggregates. Enriched in in α-synuclein protein – not pathogenic but high levels of α-synuclein is pathogenic.

71
Q

Causes of parkinson’s

A
  1. Early/juvenille onset recessive mitochondrial conditions
  2. Late/later onset (usually) autosomal dominant PD
  3. Mutations that cause ‘PD plus’ conditions
72
Q

How does early onset mitochondrial PD occur

A

Loss of function - mutations in 2 proteins central to activating mitophagy - PINK1 and Parkin = cause early onset PD (EO PD)

73
Q

Causes for late onset genetic PD

A

Mutation in SNCA (α-synuclein) gene amplification – confirm is pathogenic
Mutation in LRRK2 and VPS35 gain of function
GBA loss of function mutation

74
Q

GBA and α-synuclein

A

GBA encode GCase = α lysosomal enzyme – α-synuclein is degraded in the lysosome
Unhealthy = low GCase = lysosome impaired = accumulate α-synuclein

75
Q

Pathogenic feed forward loop of α-synuclein

A

Increase α-synuclein = decrease GCase = decrease lysosomal function

76
Q

The effect of Neuroinflammation and association with PD

A 
Neuroinflammation = activation of immune system within NS - microglia active
Activation = neurotoxic factors = neuronal damage/death - neurotoxic insult = microglial activators - α-synuclein & other proteins
77
Q

Neuroinflammation and association with Alzheimers

A

Many alzheimer’s risk factors cause high levels of circulating inflammatory cytokines
Increase BP, CVS, diabetes, smoking - increase inflammation

78
Q

Major functional changes in cancers

A
  1. Increase growth – loss of growth regulation, stimulation of environment promoting growth
  2. Failure to undergo apoptosis or senescence
  3. Loss of differentiation – including alterations in cell migration and adhesion
  4. Failure to repair DNA damage – including chromosomal instability
79
Q

Capture of c-src by retrovirus

A

Reverse transcription - dsDNA provirus, accidental integration of v-src next to c-src = fusion - packaged into capsid = oncogenic

80
Q

4 types of proteins involved in transduction of growth signals

A

Growth factors – EGF
Growth factor receptors – ErbB
Intracellular signal transducers – Ras and Raf – activate the ERK MAP kinase pathway leading to induction of additional genes
Nuclear transcription factors – ERK from the kinase pathway

81
Q

Codon mutations for bladder carcinoma

A

Glycine into valine

82
Q

Codon mutation for lung cancer

A

Glycine into cysteine

83
Q

RAS oncogene mechanism

A
  1. Binding of extracellular growth factor signal
  2. Promotes recruitment of RAS proteins to the receptor complex
  3. Recruitment promotes Ras to exchange GDP (inactive Ras) with GTP (active Ras)
  4. Activated Ras then initiates the remained of the signalling cascade (mitogen activated protein kinases)
  5. These kinases ultimately phosphorylate targets, such as transcription factor to promote expression of genes important for growth and survival
84
Q

Mutated RAS

A

Hyperactive RAS - loss of GTPase

Activity of RAS protein no return to inactive RAS GDP - ALWAYS ON = TUMORIGENESIS

85
Q

MYC oncogene mechanism

A

Encode helix loop helix leucine zipper transcriptionfactor - dimerises with partner protein Max = transactivate gene expression

86
Q

MYC deregulation

A

chromosomal translocation

Under control of foreign transcriptional promoters = deregulation of oncogene - drive relentless proliferation

87
Q

MYC activation in Burkitt’s lymphoma

A

Associated with EBV

Chromosomal translocation put mYC gene under regulation of Ig heavy chain - cmyc deregulated

88
Q

Retinoblastoma cancer

A

Rare childhood cancer – immature retinoblasts grow quickly and do not turn into mature retinal cells
Reflect light back in white = leukocoria
Hereditary mutation on chromosome 13, retinoblastoma 1 gene

89
Q

Retinoblastoma gene in cell cycle

A

Rb protein – regulate the cell cycle, inhibit G1 to S phase transition – regulate activity of E2F transcription factor
Cyclin D1 – 1st cyclin synthesised – drive progression into G1 with cdks4/6. Then arrest of cell cycle due to DNA damage
Substrate for cyclin D = RB protein – Cyclin D and E families phosphorylate RB – inactive
Active Rb = hypophosphorylated – bound to E2F – block progression to S phase

90
Q

Regulation of P53

A

Usually p53 levels low due to MDM2 protein – ubiquitin ligase – + ubiquitin to lysine residues of molecule and targeted for proteasomal degradation.

91
Q

Activation of P53

A

Stress signals can activate p53 - sensed by kinases = phosphorylate p53 - disrupt interaction with MDM2
ATM/ATR activate oncogenes - phosphorylate p53 directly/indirectly move back into nucleus to regulate process - DNA repair, apoptosis, cell cycle arrest

92
Q

Therapeutic strategies to increase P53s life/activation

A

Refold P53 into wild or regulate regulators of P53
wild type = increase 1/2 life
Nutlin = MDM2 antagonist
CRM1 - nuclear export inhibitor - accumulate P53 in nucleus

93
Q

Leukaemia

A

malignant disorders of haematopoietic stem cells characteristically associated with increased WBC in bone marrow or/and peripheral blood
Clonal disease - all malignant cells derive from single mutant SC

94
Q

Aetiology - genetic risk factors of leukaemia

A

Gene mutations involving oncogenes or tumour suppressors
Chromosome abberations - translocations and numerical disorders (BCR-ABL in CML)
Inherited immune system problems - ataxia telaniectasia, wiskott aldrich syndrome

95
Q

Environmental risk factors for leukaemia

A
  • Radiation exposure – acute radiation accidents or atomic bomb survivors
  • Exposure to chemicals and chemotherapy - Cancer chemotherapy with alkylating agents – industrial exposure to benzene
  • Immune system suppression – e.g. after organ transplant
96
Q

Acute leukaemia

A

Undifferentiated leukaemia - characterised by uncontrolled clonal and accumulation of Immature WBC - lymphoblasts or myeloid blasts in bone marrow and blood

97
Q

Symptoms of acute leukaemia

A

Thrombocytopenia - purpura, epistaxis, bleeding from gums
Neutropenia - recurrent infections, fever
Anaemia - lassitude, weakness, tiredness, shortness of breath

98
Q

Acute lymphoblastic leukaemia

A

Commonest cancer of childhood - cancer of immature lymphocytes - B cell and T cell leukaemia
Treat with chemotherapy

99
Q

Acute myeoblastic leukaemia

A

Very rare cancer of immature myeloid WBC

Treat = chemotherapy, monoclonal antibodies +/- allogeneic bone marrow transplant

100
Q

Chronic leukaemia

A

Differentiate leukaemia - characterised by uncontrolled clonal and accumulation of mature WBC - increase number of differentiated cells

101
Q

Chronic lymphocytic leukaemia symptoms

A

Large numbers of mature lymphocytes in bone marrow and peripheral blood.
Recurrent infections due to neutropenia, and suppression of normal lymphocyte function
Anaemia thrombocytopenia
Lymph node enlargement and hepatosplenomegaly

102
Q

Chronic myeloid/granulocytic leukaemia - symptoms and diagnosis

A

Often asymptomatic and discovered through routine blood test
Increase WBC count in blood and bone marrow, presence of Philadelphia chromosome
Treatment = targeted therapy - IMATINIB

103
Q

BCR-ABL unregulated tyrosine kinase effects

A

Proliferation of progenitor cell in absence of growth factors
decrease apoptosis
decrease adhesion to bone marrow stroma

104
Q

Imatinib mechanism for targeted therapy

A

Small molecule inhibitor
targets Abl-CML treatment - 95% of CML have detectable philadelphia chromosome
Imatinib competes with ATP - tyrosine is not phosphorylated and cannot phosphorylate substrate

105
Q

Lymphoma

A

Cancer of WBC - affect mature blood cells - B and T cells

106
Q

Lymph node functions

A

Blood filtration/purification
Absorption and transport of lipids
Removal of excess fluids from tissues
Immune system activation

107
Q

Hodgkin lymphoma

A

17% of lymphomas
Clonal B cell malignancy - presentation = non-painful enlarged lymph node
Risk = 50% cases due to EBV

108
Q

Diagnosis and treatment of hodgkin lymphoma

A

Diagnosis - Biopsy - find multinucleated reed sternberg cell

Treatment - chemotherapy, +/- radiotherapy. SC transplant

109
Q

Non Hodgkin lymphoma

A

83% of lymphomas - incidence increases with age
Enlarged lymph nodes - some forms slow and the others fast - general lymphoma symptoms
Risk factors = virus infections, EBV in burkitt lymphoma. Human T cell leukaemia in adult T cell lymphoma

110
Q

Causes of non hodgkin lymphoma

A

Chromosomal translocations
Tissue specific enhancer = activate promoter of rearranged segment of chromosomes - cases of follicular lymphoma - start to regulate and enhance transcription of genes located on other chromosome.

111
Q

Example of chromosome translocation for non hodgkin lymphoma - follicular lymphoma

A

Chr 18 has BCL-2 gene
Enhancer in chr 14
BCL-2 = apoptosis inhibitor
Enhance transcription of apoptosis inhibitor = decreases apoptosis

112
Q

Low grade lymphoma

A

Normal tissue architecture partially preserved - normal cell of origin recognisable
divide slowly
May be present for many months before diagnosis
behave in indolent fashion

113
Q

High grade lymphoma

A

Loss of normal tissue architecture - normal cell of origin hard to determine
Divide rapidly
present for a matter of weeks before diagnosis
May be life threatening

114
Q

Diagnosis and treatment of non hodgkin lymphoma

A 
Diagnosis = immunophenotyping, cytogenetics, light chain restriction, PCR
Treatment = chemotherapy, radiotherapy, SC transplant, monoclonal Ab therapy - RITUXIMAB
115
Q

Multiple myeloma

A

Tumour of bone marrow that involves plasma cells
Presentation = absence of initial symptoms - later = bone pain, bleeding, freq infections and anaemia
Risk factors = obesity, radiation exposure, family history, and certain chemicals

116
Q

3 aspects of myeloma

A
  1. Suppression of normal bone marrow, blood cell and immune cell function - anaemia, bleeding tendency and recurrent infections
  2. Bone resorption and release calcium
  3. Pathological effects of paraprotein
117
Q

Bone resorption and release of calcium effects in myeloma

A

Myeloma produce cytokines (IL6) to bone marrow stromal cells to release RANKL to osteoclast activation and suppress OPG.
Ca2+ released from bone leads to hypercalcaemia leading to mental disturbance and multiple symptoms

118
Q

Pathological effects of paraprotein

A

Single monoclonal Ig in serum - high levels - malignancy
Precipitate in kidney tubules leading to renal failure - deposited as amyloid in tissues.
2% of cases develop hypervisocosity syndrome
Increase viscosity of blood leading to stroke and heart failure

119
Q

Diagnosis of myeloma

A

Serum electrophoresis for paraprotein
Bone marrow biopsy fo rhigh levels of plasma cells
Flow cytometry and cytogenetics to detect cause
Urine electrophoresis
Erythrocyte sedimentation rate - increase staking RBC
Radiological investigation of skeleton for lytic lesions

120
Q

Treatment for myeloma

A

Radiotherapy – localised bone pain
chemotherapy combinations (thalidomide, lenalidomide and bortezomib) – when there is dissemination
targeted therapies, immunotherapy (CAR-T), and allogenic haemopoietic SC transplantation in young patients.

MOLECULAR BASIS OF DISEASE (3 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions